Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019
November 05 2019 - 8:00AM
Business Wire
- Research, interactive features and charitable
opportunity support advancement of care -
Horizon Therapeutics plc (Nasdaq: HZNP) will join the leading
voices in the nephrology community this week to inform and build
data-based discourse on managing the challenges of gout and kidney
disease during the American Society of Nephrology (ASN) Kidney
Week, to be held Nov. 5-10 in Washington, D.C.
“While gout has been well understood by its rheumatological
manifestations, it is fundamentally a disease caused by the
kidney’s inefficiency in eliminating uric acid,” said Paul Peloso,
M.D., M.Sc., vice president and therapeutic area head,
rheumatology, Horizon. “Growing evidence illustrates the
complications caused by gout for those living with chronic kidney
disease, particularly those who have received a kidney transplant.
We are working to shepherd greater engagement through scientific
contributions, awareness building and education to help identify
this connection in high risk patients and intervene with
confidence.”
Highlights of Horizon’s presence during Kidney Week include
poster presentations that depict the etiology of gout among kidney
disease patients, particularly among those who have received a
transplant. These presentations include:
- Assessing the relationship between Gout and Return to
Hemodialysis among Renal Transplant Patients Abstract:
FR-PO1171, J. Li
- Renal Transplant Complications in Patients with and without
Gout Abstract: FR-PO1170, M. Francis-Sedlak
- Evidence of Urate Deposition in the Kidneys in Gout Patients
Abstract: PUB426, B. Marder
- Incident gout after renal transplantation in gout-naïve
patients: large database analysis Abstract: PUB329, B.
LaMoreaux
Beyond contributions to scientific exchange, Horizon invests in
education and awareness efforts to raise the conversation about
gout across the community and build greater appreciation for the
priorities in patient care. During Kidney Week, Horizon will
support advancements in care through interactive education and
charitable contributions, to include:
- A dynamic, 15-foot interactive nephron machine that
demonstrates both the kidney’s retention of uric acid and efficient
excretion of allantoin.
- Contributions to KidneyCure, the ASN Foundation, from Horizon
driven by participant interaction. Horizon will make a donation to
KidneyCure of up to $50 for every attendee who interacts with the
nephron machine, for a total donation up to $25,000. KidneyCure is
an organization that supports the future of the field as talented
fellows, young investigators, and nephrology educators challenge
and change the evolution of kidney care.
About Uncontrolled Gout
Gout is a chronic, progressive inflammatory form of arthritis
that is caused by excess uric acid in the body and needs to be
managed aggressively.1 Over time uric acid can build up and form
deposits, called tophi, inside the body and joints, which can have
harmful effects including causing damage to the underlying bone.
Patients with uncontrolled gout continue to have abnormally high
levels of uric acid and continued symptoms of gout despite the use
of conventional therapies.2
About Horizon
Horizon is focused on researching, developing and
commercializing medicines that address critical needs for people
impacted by rare and rheumatic diseases. Our pipeline is
purposeful: we apply scientific expertise and courage to bring
clinically meaningful therapies to patients. We believe science and
compassion must work together to transform lives. For more
information on how we go to incredible lengths to impact lives,
please visit www.horizontherapeutics.com, follow us @HorizonNews on
Twitter, like us on Facebook or explore career opportunities on
LinkedIn.
References
1 Keuhn B. Chronic Disease Approaches Needed to Curb Gout’s
Growing Burden. Journal of the American Medical Association.
2018;319(13):1308-1309.
2 Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and
hyperuricemia in the US general population: the National Health and
Nutrition Examination Survey 2007-2008. Arthritis Rheum.
2011;63(10):3136-3141.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191105005235/en/
Tina Ventura Senior Vice President, Investor Relations
Investor-relations@horizontherapeutics.com
Ruth Venning Executive Director, Investor Relations
Investor-relations@horizontherapeutics.com
U.S. Media Contact: Amanda Phraner Associate
Director, Public Relations and Social Media
media@horizontherapeutics.com
Ireland Media Contact: Gordon MRM Ray Gordon
ray@gordonmrm.ie
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2023 to Apr 2024